Copyright
©The Author(s) 2020.
World J Gastrointest Pharmacol Ther. Aug 8, 2020; 11(3): 48-58
Published online Aug 8, 2020. doi: 10.4292/wjgpt.v11.i3.48
Published online Aug 8, 2020. doi: 10.4292/wjgpt.v11.i3.48
Parameter | Result | Range |
ALT in median (IQR) (up to 45 U/L) | 16.5 (13-24.8) | 8-184 |
AST in median (IQR) (up to 75 U/L) | 27 (20.5-34) | 6-226 |
TB in median (IQR) (up to 1.4 mg/dL) | 0.4 (0.3-0.5) | 0.1-3.4 |
DB in median (IQR) (up to 1.4 mg/dL) | 0.1 (0.1-0.1) | 0-1.7 |
ALP in median (IQR) (up to 640 U/L) | 161 (88-239) | 50-439 |
GGT in median (IQR) (up to 50 U/L) | 15 (12.3-19.8) | 8-331 |
Albumin in mean ± SD (3.5-4.5 g/dL) | 3.75 ± 0.78 | 1.3-5.3 |
PT in mean ± SD (s) | 13.1 ± 0.59 | 11.7-14.8 |
PC in mean ± SD | 92.8 ± 7.41 | 76-100 |
INR in mean ± SD | 1.02 ± 0.05 | 1-1.2 |
- Citation: El-Shabrawi MH, Tarek S, Abou-Zekri M, Meshaal S, Enayet A, Mogahed EA. Hepatobiliary manifestations in children with inflammatory bowel disease: A single-center experience in a low/middle income country. World J Gastrointest Pharmacol Ther 2020; 11(3): 48-58
- URL: https://www.wjgnet.com/2150-5349/full/v11/i3/48.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v11.i3.48